作者: Shaowen Xiao , Shanwen Zhang , Xiaofan Li , Yongheng Li
DOI: 10.3978/J.ISSN.1000-9604.2013.12.05
关键词:
摘要: Objective: To assess the safety and clinical antiangiogenic effect of recombinant adenovirus-p53 (rAd-p53) combined with hyperthermia plus or not radiotherapy in advanced cancer. Methods: Expression Vascular epithelial growth factor (VEGF) after intratumoral injection rAd-p53 was assayed by immunohistochemistry (IHC) imaging. Forty-four patients cancer were enrolled into this study. The intratumorally injected (Gendicine) at a dose 1×10 12 vp once week, total 4-54 (mean 7.7) times. Total 4-29 8.5) times given to patients. Among 44 patients, 30 concurrently added 30-76 Gy/15-38 f/3-8 w 58 Gy). Results: Before rAd-p53, VEGF IHC positive cell scores 2.80 1.50, respectively (P=0.031). treatment achieved CR rate 13.60% (6/44), PR 29.6% (13/44), thus effective 43.2%. In addition 6 CR, 19 (19/38, 50.0%) had low density area (LDA) more than 50% on CT image within tumor indicating tissue necrosis. Conclusions: Our data indicate that inhibits expression angiogenesis, promotes necrosis shrinkage induced cancer.